에 대한 최신 뉴스 Nurix Therapeutics (NASDAQ:NRIX) 주식

NURIX THERAPEUTICS INC

Nurix Therapeutics

Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies.

Stuttgart,,Germany,-,03-11-2021:,Person,Holding,Cellphone,With,Company,Logo

Equities

News

Markets

ETFs

ADPT

ARKQ

NRIX

NVDA

PATH

수요일(23일) 캐시 우드가 이끄는 아크 인베스트는 엔비디아(NASDAQ:NVDA)와 AMD(NASDAQ:AMD)에 대한 노출을 증가시켰다. 이러한 거래는 반도체 산업에서 지속적인 도전 과제, 특히 미국의 제재가 중국에 대한 칩 판매에 영향을 미치고 있는 상황에서 이루어졌다.

캐시 우드, 엔비디아·AMD 주식 추가 매입···수출 규제 앞두고 중국 기술 업체들은 칩 대량 비축

Responding To Regulatory Scrutiny

Broad U.S. Equity ETFs

Education

Specialty ETFs

Tech

ARKG

ARKK

CDNA

COIN

CRSP

HOOD

IONS

NTRA

PLTR

RBLX

ROKU

RXRX

SHOP

TSLA

TWST

VYCT

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 혁신 분야에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다. 이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&amp;P 500과 비교

The Boeing Company (BA)

Earnings

Pre-Market Outlook

Trading Ideas

CLEU

IPHA

KARO

오늘 월요일 아침 미국 주식 선물이 약간 하락하고 있는 가운데, 오늘 투자자들의 관심을 끌 수 있는 주식은 다음과 같습니다: 1. 월스트리트는 카루(NASDAQ:KARO)가 분기 실적을 주당 39센트의 이익과 6,323만 달러의 매출로 발표할 것으로 예상하고 있다. Benzinga Pro의 데이터에 따르면, 카루(Karooooo)의 주식은 시간외 거래에서 14.4% 상승하여 50.00달러에 거래되었다.

월요일 주목해야 할 주식: 보잉, 누릭스 테라퓨틱스, 보잉, 인네이트 파마 및 차이나 리버럴

Nurix Therapeutics Inc

General

OCTO

Eightco Holdings Enters Settlement Agreements With Third Parties, Including CFO And Board Member; Liabilities Reduced From Over $2.2M To About $1.1M Under Settlement

PJT Partners (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PJT#NYSE">PJT</a>) has outperformed the market over the past 5 years by 8.85% on an annualized basis producing an average annual return of 21.93%. Currently, PJT Partners has a market capitalization of $3.70 billion. 
Buying $1000 In PJT: If an investor had bought $1000 of PJT stock 5 years ago, it would be worth $2,675.52 today based on a price of $151.06 for PJT at the time of writing.
<h3>PJT Partners's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1749158110_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Here's How Much You Would Have Made Owning PJT Partners Stock In The Last 5 Years

GlobeNewswire Issues Report Saying "We Are Advised By ZJK Industrial Co., Ltd. That Journalists And Other Readers Should Disregard The News Release, "ZJK Industrial Co., Ltd. Ramps Up Production To Support Nvidia's B40 Project, Expecting Significant YoY Revenue Growth" Issued On June 5, 2025 At 08:00 am EDT"

<a href="https://www.benzinga.com/etfs">Exchange-traded funds</a> with significant exposure to Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) could be in for a rough ride, not due to production setbacks or margin squeeze, but thanks to a new set of political fireworks between <a href="https://www.benzinga.com/news/politics/25/06/45800612/trump-says-musk-has-trump-derangement-syndrome-as-battle-over-bill-heats-up-had-a-great-relationship-dont-know-if-we-will-anymore">Elon Musk and Donald Trump</a>.
On Tuesday, <a href="https://www.benzinga.com/trading-ideas/movers/25/06/45795638/tesla-stock-slumps-amid-political-turmoil-whats-going-on">TSLA stock plummeted</a> as President Trump publicly criticized Musk, stating he was &#8220;disappointed&#8221; with the Tesla CEO&#8217;s &#8220;furious bashing&#8221; of the tax legislation. The remark came on the heels of reports that Musk, in behind-the-scenes talks, showed intense opposition to the bill&#8217;s incentives for clean energy, which he feels benefit union-supported automakers at Tesla&#8217;s expense. On Thursday, the Tesla stock is down a sharp 15%.
While Musk has never hesitated to court controversy, the new spat adds one more level of risk for investors, especially those who are exposed through ETFs that hold Tesla as a strategic holding.
Also Read: <a href="https://www.benzinga.com/news/politics/25/06/45795080/whatever-you-think-of-elon-musk-you-must-support-his-fight-against-the-big-beautiful-bill-says-black-swan-author-nassim-taleb">&#8216;Whatever You Think Of Elon Musk, You Must Support His Fight Against The Big Beautiful Bill,&#8217; Says &#8216;Black Swan&#8217; Author Nassim Taleb</a>
<h2 class="wp-block-heading">ETFs In The Crosshairs</h2>
Tesla is still a major contributor to a number of actively and passively managed ETFs, particularly those that concentrate on innovation, EVs, and clean energy. Some of the most exposed:
ARK Innovation ETF (BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#BATS">ARKK</a>) – Tesla is the single largest holding, frequently making up 12% or more of the portfolio.
iShares Self-Driving EV and Tech ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IDRV#NYSE">IDRV</a>) – Tesla is frequently in the top five, but it has cut its weightage to 3.5% in the last rejig.
KraneShares Electric Vehicles and Future Mobility ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KARS#NYSE">KARS</a>) – TSLA is prominent, at almost 4% weightage.
They&#8217;ve gone through volatility already with Tesla&#8217;s stock price, which fell almost 20% through the past five trading days. But political tension adds a wilder variable, one that&#8217;s difficult to price into models and more difficult to hedge in a diversified basket.
<h2 class="wp-block-heading">Passive Exposure, Active Headaches</h2>
For individual investors who are not monitoring every political headline, indirect exposure to these risks through ETFs can be a surprise in store.
This is the classic example of political risk spilling over into passive portfolios. When Tesla catches a cold, ARKK gets it, and when Musk gets involved in a political fight, it&#8217;s the ETF investors who will need a flu shot.
<h2 class="wp-block-heading">Looking Ahead</h2>
In the near term, ETF issuers won&#8217;t rebalance on political noise alone. But ongoing stress about Tesla&#8217;s regulatory and political positioning might impact flows.
For investors in ETFs, the takeaway can be less about Musk himself and more learning what&#8217;s driving their portfolios from beneath the hood. Because sometimes, earnings or interest rates aren&#8217;t driving your fund, it&#8217;s Elon Musk, a tweet from some social media account, and a news headline with Donald Trump&#8217;s name on it.
Read Next: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/etfs/new-etfs/25/06/45801050/crash-proof-investing-new-innovator-etf-promises-downside-buffer">Crash-Proof Investing? New Innovator ETF Promises Downside Buffer</a></li>
</ul>
Photo: Shutterstock

IDRV

KARS

Trump-Musk Feud Gets Ugly: ETFs Exposed With Tesla Caught In The Crossfire

Offerings

Trump Media & Technology Files For Primary Mixed Shelf Offering Of Up To $12B

Xtract One Technologies (TSX:<a class="ticker" href="https://www.benzinga.com/stock/XTRA#TSX">XTRA</a>) reported quarterly losses of $(0.02) per share. This is a 100 percent decrease over losses of $(0.01) per share from the same period last year. The company reported $3.47 million in sales this quarter. This is a 26.00 percent decrease over sales of $4.68 million the same period last year.

TSX:XTRA

Xtract One Technologies Q3 EPS $(0.02) Down From $(0.01) YoY, Sales $3.47M Down From $4.68M YoY

Trump Media and Technology Group Corp. (Nasdaq, NYSE Texas: <a href="https://www.benzinga.com/stock/djt#Nasdaq,%20NYSE%20Texas">DJT</a>) ("Trump Media" or the "Company"), operator of the social media platform Truth Social, the streaming platform Truth+, and the FinTech brand Truth.Fi, announced today that it has filed a registration statement on form S-3 ("Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") related to debt and equity subscription agreements recently entered into with approximately fifty investors that yielded approximately $2.3 billion in total proceeds—one of the largest Bitcoin treasury deals for a public company. The proceeds will be used for the Company's creation of a Bitcoin treasury and for general corporate purposes.
In accordance with registration obligations in the previously-disclosed agreements, the Registration Statement seeks to register for resale by the investors approximately 56 million shares of equity and 29 million shares underlying convertible notes.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Trump Media Files SEC Registration Statement To Enable Resale Of Shares From $2.3B Bitcoin-Focused Financing Deal With 50 Investors

Combination will fast-track Genpact's expansion of advanced technology solutions, amplifying data and AI capabilities, domain expertise, and strategic partnerships&nbsp;&nbsp;
NEW YORK, June 5, 2025 /PRNewswire/ --&nbsp;Genpact (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/G#NYSE">G</a>), a global advanced technology services and solutions company, today announced it has acquired XponentL Data, a data products and artificial intelligence (AI) solutions provider. XponentL brings differentiated domain-led data strategy, design, and engineering capabilities; deep industry experience; and strategic partnerships. This acquisition builds on Genpact's pivot to data, AI, and other advanced technologies, further enhancing Genpact's ability to help clients across the lifecycle of AI transformation, from strategy through implementation.

Genpact Acquires XponentL Data; Financial Details Of The Transaction Were Not Disclosed.

Management

NAVI

Navient Elects Edward Bramson Chair Of The Board Of Directors

IAC Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IAC#NASDAQ">IAC</a>) ("IAC") announced today that its wholly owned subsidiary, Dotdash Meredith Inc. ("DDM"), has agreed to sell $400 million aggregate principal amount of 7.625% senior secured notes due 2032 (the "Notes") in a private offering (the "Offering").&nbsp; The Notes will bear interest at an interest rate of 7.625% per annum and will be issued at 100.00% of their face value.&nbsp; DDM's obligations under the Notes will be guaranteed on a senior secured basis by certain of DDM's subsidiaries.
DDM intends to use the proceeds of the offering, together with the borrowings under DDM's new $700.0 million term loan B facility and cash on hand, to repay all of the indebtedness outstanding under DDM's existing $1.18 billion term loan B-1 facility and to pay related fees and expenses.&nbsp; The closings of each of the Offering and new term loan B facility are expected to occur on or about June 16, 2025, each subject to the satisfaction of customary closing conditions.

IAC's Dotdash Meredith, Has Agreed To Sell $400M Aggregate Principal Amount Of 7.625% Senior Secured Notes Due 2032

Air T, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRT#NASDAQ">AIRT</a>) announced on June 2nd the successful renegotiation of a key financing agreement involving its wholly owned subsidiary, AAM 24-1, LLC.
The updated agreement, reached with the Company's existing institutional investors, grows the transaction from $30,000,000 to $100,000,000, extends repayment timelines and increases financial flexibility. These changes support Air T's long-term capital foundation while maintaining alignment with its strategic objectives and commitment to growth.

Financing

AIRT

Air T Expands Key Financing Deal From $30M To $100M, Boosting Flexibility And Supporting Long-Term Growth Strategy

<h3>Gainers</h3>
<ul>
<li>Jiade (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JDZG#NASDAQ">JDZG</a>) shares moved upwards by 10.5% to $0.38 during Thursday's after-market session. The company's market cap stands at $9.2 million. </li>
<li>Rent the Runway (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RENT#NASDAQ">RENT</a>) stock increased by 10.15% to $7.7. The market value of their outstanding shares is at $30.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Yunji (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/YJ#NASDAQ">YJ</a>) stock moved upwards by 7.85% to $2.06. The market value of their outstanding shares is at $40.5 million. </li>
<li>NWTN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWTN#NASDAQ">NWTN</a>) stock rose 6.17% to $1.72. The company's market cap stands at $492.2 million. </li>
<li>E-Home Household Service (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EJH#NASDAQ">EJH</a>) shares increased by 5.94% to $2.85. </li>
<li>Jianzhi Education Tech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JZ#NASDAQ">JZ</a>) shares rose 5.55% to $0.38. The company's market cap stands at $10.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Lululemon Athletica (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LULU#NASDAQ">LULU</a>) stock decreased by 22.9% to $255.09 during Thursday's after-market session. The company's market cap stands at $31.9 billion. As per the news, the Q1 earnings report came out today. </li>
<li>Golden Heaven Group Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDHG#NASDAQ">GDHG</a>) shares declined by 13.73% to $1.32. The market value of their outstanding shares is at $21.6 million. </li>
<li>Petco Health and Wellness (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WOOF#NASDAQ">WOOF</a>) shares decreased by 11.88% to $3.19. The market value of their outstanding shares is at $889.9 million. As per the news, the Q1 earnings report came out today. </li>
<li>Top Win International (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SORA#NASDAQ">SORA</a>) stock decreased by 9.42% to $6.35. The market value of their outstanding shares is at $157.8 million. </li>
<li>Zumiez (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZUMZ#NASDAQ">ZUMZ</a>) shares decreased by 6.3% to $12.05. The company's market cap stands at $230.8 million. As per the news, the Q1 earnings report came out today. </li>
<li>Genius Group (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/GNS#AMEX">GNS</a>) shares fell 5.53% to $0.34. The market value of their outstanding shares is at $24.3 million. 
See Also: <a href="http://www.benzinga.com/money/best-consumer-cyclical-stocks/" title="www.benzinga.com/money/best-consumer-cyclical-stocks/">www.benzinga.com/money/best-consumer-cyclical-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Movers

GDHG

JDZG

LULU

NWTN

RENT

SORA

WOOF

ZUMZ

12 Consumer Discretionary Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Bluejay Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJDX#NASDAQ">BJDX</a>) stock rose 41.5% to $2.15 during Thursday's after-market session. The market value of their outstanding shares is at $3.2 million. </li>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares moved upwards by 30.86% to $0.26. The company's market cap stands at $16.7 million. </li>
<li>Eyenovia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EYEN#NASDAQ">EYEN</a>) shares increased by 28.97% to $4.05. The company's market cap stands at $11.6 million. </li>
<li>Pediatrix Medical Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MD#NYSE">MD</a>) shares moved upwards by 8.47% to $15.1. The company's market cap stands at $1.2 billion. </li>
<li>Rani Therapeutics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RANI#NASDAQ">RANI</a>) shares increased by 7.27% to $0.57. The company's market cap stands at $19.0 million. </li>
<li>RAPT Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RAPT#NASDAQ">RAPT</a>) stock rose 6.86% to $1.09. The company's market cap stands at $144.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Liminatus Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIMN#NASDAQ">LIMN</a>) shares declined by 18.7% to $20.0 during Thursday's after-market session. The company's market cap stands at $534.2 million. </li>
<li>Senti Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNTI#NASDAQ">SNTI</a>) shares decreased by 10.12% to $3.2. The market value of their outstanding shares is at $83.4 million. </li>
<li>Pheton Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTHL#NASDAQ">PTHL</a>) shares decreased by 9.44% to $8.06. The market value of their outstanding shares is at $116.8 million. </li>
<li>Universe Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) stock fell 8.15% to $3.86. The company's market cap stands at $58.7 million. </li>
<li>NewGenIvf Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NIVF#NASDAQ">NIVF</a>) shares decreased by 7.83% to $2.12. The market value of their outstanding shares is at $1.5 million. </li>
<li>Scinai Immunotherapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) shares declined by 7.7% to $3.0. The company's market cap stands at $2.8 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BJDX

EYEN

GLYC

LIMN

NIVF

PTHL

RANI

RAPT

SCNI

SNTI

12 Health Care Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Momentus (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MNTS#NASDAQ">MNTS</a>) shares moved upwards by 14.1% to $1.86 during Thursday's after-market session. The company's market cap stands at $10.2 million. </li>
<li>Virgin Galactic Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPCE#NYSE">SPCE</a>) shares increased by 11.5% to $3.49. The company's market cap stands at $145.0 million. </li>
<li>EuroDry (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EDRY#NASDAQ">EDRY</a>) shares moved upwards by 8.33% to $8.84. The market value of their outstanding shares is at $24.9 million. The company's, Q1 earnings came out today. </li>
<li>Quanex Building Prods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NX#NYSE">NX</a>) stock moved upwards by 7.19% to $18.32. The company's market cap stands at $865.2 million. The company's, Q2 earnings came out today. </li>
<li>Founder Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FGL#NASDAQ">FGL</a>) stock increased by 7.12% to $1.03. The company's market cap stands at $19.9 million. </li>
<li>Sidus Space (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIDU#NASDAQ">SIDU</a>) stock rose 6.44% to $1.57. The market value of their outstanding shares is at $28.7 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Concrete Pumping Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBCP#NASDAQ">BBCP</a>) stock decreased by 12.3% to $6.2 during Thursday's after-market session. The company's market cap stands at $328.9 million. The company's, Q2 earnings came out today. </li>
<li>iPower (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IPW#NASDAQ">IPW</a>) shares declined by 11.96% to $0.5. The company's market cap stands at $15.6 million. </li>
<li>Linkers Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNKS#NASDAQ">LNKS</a>) stock fell 6.89% to $0.59. The company's market cap stands at $7.9 million. </li>
<li>Lucas GC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LGCL#NASDAQ">LGCL</a>) stock decreased by 6.72% to $0.58. The company's market cap stands at $46.4 million. </li>
<li>ATIF Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZBAI#NASDAQ">ZBAI</a>) shares fell 6.71% to $0.63. The market value of their outstanding shares is at $10.9 million. </li>
<li>LanzaTech Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LNZA#NASDAQ">LNZA</a>) stock decreased by 6.09% to $0.23. The company's market cap stands at $52.9 million. 
See Also: <a href="http://www.benzinga.com/money/best-industrials-stocks/" title="www.benzinga.com/money/best-industrials-stocks/">www.benzinga.com/money/best-industrials-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BBCP

EDRY

LGCL

LNKS

LNZA

MNTS

SIDU

SPCE

ZBAI

12 Industrials Stocks Moving In Thursday's After-Market Session

<h3>Gainers</h3>
<ul>
<li>Ascent Solar Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASTI#NASDAQ">ASTI</a>) stock moved upwards by 9.9% to $1.77 during Thursday's after-market session. The company's market cap stands at $3.2 million. </li>
<li>Abits Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ABTS#NASDAQ">ABTS</a>) shares increased by 4.97% to $4.22. The company's market cap stands at $10.0 million. </li>
<li>Nano Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NA#NASDAQ">NA</a>) shares moved upwards by 4.95% to $7.2. The company's market cap stands at $120.1 million. </li>
<li>Expensify (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXFY#NASDAQ">EXFY</a>) shares rose 4.82% to $2.39. The market value of their outstanding shares is at $220.8 million. </li>
<li>SmartRent (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SMRT#NYSE">SMRT</a>) shares moved upwards by 4.62% to $0.97. The market value of their outstanding shares is at $182.5 million. </li>
<li>Saverone 2014 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SVRE#NASDAQ">SVRE</a>) stock moved upwards by 4.42% to $1.18. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Docusign (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) stock declined by 16.0% to $78.05 during Thursday's after-market session. The market value of their outstanding shares is at $15.8 billion. As per the news, the Q1 earnings report came out today. </li>
<li>MicroCloud Hologram (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOLO#NASDAQ">HOLO</a>) stock decreased by 14.63% to $4.44. The market value of their outstanding shares is at $22.7 million. </li>
<li>ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) shares declined by 12.76% to $99.94. The market value of their outstanding shares is at $8.9 billion. As per the press release, Q1 earnings came out today. </li>
<li>Samsara (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) shares declined by 11.54% to $41.8. The company's market cap stands at $23.7 billion. The company's, Q1 earnings came out today. </li>
<li>Braze (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) stock fell 9.06% to $32.84. The company's market cap stands at $3.4 billion. As per the news, the Q1 earnings report came out today. </li>
<li>BitMine Immersion Technologies, Inc. Common Stock (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/BMNR#AMEX">BMNR</a>) stock fell 8.91% to $7.06. 
See Also: <a href="http://www.benzinga.com/money/tech-stocks/" title="www.benzinga.com/money/tech-stocks/">www.benzinga.com/money/tech-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ABTS

ASTI

BMNR

BRZE

DOCU

EXFY

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

SMRT

SVRE

TTAN

12 Information Technology Stocks Moving In Thursday's After-Market Session

VEON Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VEON#NASDAQ">VEON</a>) ("VEON"), a global digital operator, announces the public filing of a registration statement on Form F-4 (the "Registration Statement") with the U.S. Securities and Exchange Commission ("SEC") in connection with the listing of Kyivstar Group Ltd. ("Kyivstar Group"), the parent company of Ukraine's leading digital operator JSC Kyivstar, on the Nasdaq Stock Market LLC ("Nasdaq").
This filing represents a milestone in VEON's plans to list Kyivstar Group on Nasdaq following the anticipated completion of a business combination with Cohen Circle Acquisition Corp. I (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CCIR#NASDAQ">CCIR</a>) ("Cohen Circle") that was announced on March 18, 2025. At the closing of the transaction, the business combination will result in the listing of Kyivstar Group's common shares and warrants on Nasdaq under the ticker symbols "KYIV" and "KYIVW," respectfully, as the only pure-play Ukrainian investment opportunity on U.S. stock markets.

CCIR

VEON

VEON Files Registration Statement With SEC To List Kyivstar Group On Nasdaq Following Planned Merger With Cohen Circle Under Tickers "KYIV"

Saputo (TSX:<a class="ticker" href="https://www.benzinga.com/stock/SAP#TSX">SAP</a>) reported quarterly earnings of $0.30 per share which missed the analyst consensus estimate of $0.34 by 11.76 percent. This is a 18.92 percent decrease over earnings of $0.37 per share from the same period last year. The company reported quarterly sales of $4.75 billion which beat the analyst consensus estimate of $4.74 billion by 0.27 percent. This is a 4.58 percent increase over sales of $4.54 billion the same period last year.

Earnings Beats

Earnings Misses

TSX:SAP

Saputo Q4 Adj. EPS $0.30 Misses $0.34 Estimate, Sales $4.75B Beat $4.74B Estimate

Vail Resorts Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) reported financial results for the third quarter on Thursday after the bell. Here&#8217;s a look at the key details <a href="https://www.benzinga.com/pressreleases/25/06/n45802286/vail-resorts-reports-fiscal-2025-third-quarter-results-provides-updated-fiscal-2025-guidance-and-p">from the print</a>.
Q3 Earnings: Vail Resorts reported third-quarter revenue of $1.29 billion, narrowly missing estimates of $1.3 billion, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>. The company reported third-quarter earnings of $10.54 per share, beating estimates of $10.12 per share. 
Total revenue was up 1% year-over-year. Pass product sales&nbsp;for the upcoming 2025/2026 North American ski season decreased approximately&nbsp;1%&nbsp;in units, but increased approximately&nbsp;2%&nbsp;in sales dollars.
Vail Resorts&#8217; board declared a quarterly cash dividend of $2.22 per share, payable on July 9 to shareholders of record as of June 24. 
&#8220;Results in the quarter reflect the stability provided by our season pass program as Resort net revenue, excluding Crans-Montana, remained consistent with the prior year even as visitation declined 7%,&#8221; said Rob Katz, CEO of Vail Resorts.
&#8220;Our performance throughout the 2024/2025 North American ski season reflects the strength of our advance commitment strategy, strong destination guest spending, and the impact of our resource efficiency transformation plan.&#8221;
Vail announced at the end of May that Katz was taking over as CEO for Kirsten Lynch, who decided to step down from the role. 
Vail said it expects to achieve $100 million in annualized cost efficiencies by the end of fiscal 2026 due to the company&#8217;s two-year resource efficiency transformation plan, announced in September 2024.
Outlook: The company expects fiscal 2025 net income attributable to Vail Resorts to be between&nbsp;$264 million&nbsp;and&nbsp;$298 million, and Resort Reported EBITDA for fiscal 2025 to be between&nbsp;$831 million&nbsp;and&nbsp;$851 million.&nbsp;
&#8220;The guidance reflects the lower than expected lift ticket visitation in the spring period that was partially mitigated by the Company&#8217;s focus on its resource efficiency transformation plan and strong cost discipline,&#8221; the company said.
Vail Resorts executives will further discuss the quarter on a conference call set for 5 p.m. ET.
MTN Price Action:&nbsp;<a href="http://benzinga.com/quote/MTN" target="_blank" rel="noreferrer noopener">Vail Resorts shares</a>&nbsp;were down 1.04% in after-hours, trading at $153.33 at the time of publication Thursday, according to&nbsp;<a href="http://pro.benzinga.com/" target="_blank" rel="noreferrer noopener">Benzinga Pro</a>.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45803051/docusign-stock-plummets-after-q1-earnings-report-details">DocuSign Stock Plummets After Q1 Earnings Report: Details</a></li>
<li><a href="https://www.benzinga.com/markets/earnings/25/06/45803595/broadcom-q2-earnings-revenue-eps-beat-estimates-driven-by-robust-demand-for-ai-networking-company-sees-acceleration-in-ai-revenue-ahead">Broadcom Q2 Earnings: Revenue, EPS Beat Estimates Driven By &#8216;Robust Demand&#8217; For AI Networking, Company Sees Acceleration In AI Revenue Ahead</a></li>
</ul>
Photo: Tint Media/Shutterstock.

Guidance

Travel

Sports

After-Hours Center

Vail Resorts Stock Slides On Q3 Earnings, Company Targets $100 Million In Annualized Cost Efficiencies

Enghouse Systems (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENGH#TSX">ENGH</a>) reported quarterly earnings of $0.24 per share which missed the analyst consensus estimate of $0.37 by 35.14 percent. This is a 33.33 percent decrease over earnings of $0.36 per share from the same period last year. The company reported quarterly sales of $124.82 million which missed the analyst consensus estimate of $129.48 million by 3.60 percent. This is a 0.79 percent decrease over sales of $125.81 million the same period last year.

TSX:ENGH

Enghouse Systems Q2 EPS $0.24 Misses $0.37 Estimate, Sales $124.82M Miss $129.48M Estimate

In the current market session, Frontline Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FRO#NYSE">FRO</a>) share price is at $18.13, after a 0.17% drop. Over the past month, the stock went up by 5.96%, but over the past year, it actually decreased by 30.93%. With good short-term performance like this, and questionable long-term performance, long-term shareholders might want to start looking into the company's price-to-earnings ratio.

<img src="https://www.benzinga.com/files/images/story/2025/1749157220_0.png" alt="Past Year Chart" />

<h3>Comparing Frontline P/E Against Its Peers</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 76.1 in the Oil, Gas &amp; Consumable Fuels industry, Frontline Inc. has a lower P/E ratio of 11.57. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1749157220_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Frontline Inc's Price Over Earnings

Press Releases

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Health Care

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

Akebia Therapeutics

Ardelyx

ArriVent BioPharma

CareDx

Celldex Therapeutics, Inc. - Common Stock

Celldex Therapeutics

Day One Biopharmaceuticals, Inc. - Common Stock

Day One Biopharmaceutical

Dynavax Technologies Corporation - Common Stock

Dynavax Technologies

Geron

Gyre Therapeutics

Immunome

Immatics

MiMedx Group

Mineralys Therapeutics, Inc. - Common Stock

Mineralys Therapeutics

Intellia Therapeutics, Inc. - Common Stock

Intellia Therapeutics

Novavax

Pharming Group N.V. - ADS, each representing 10 ordinary shares

Pharming

Praxis Precision Medicines, Inc. - Common Stock

Praxis Precision Medicine

Arcus Biosciences

Replimune Group

Syndax Pharmaceuticals, Inc. - Common Stock

Syndax Pharmaceuticals

Spyre Therapeutics

Taysha Gene Therapies, Inc. - Common Stock

Taysha Gene Therapies

Vir Biotechnology

Viridian Therapeutics, Inc. - Common Stock

Viridian Therapeutics

Zymeworks

Needham

Wells Fargo

Stifel

HC Wainwright & Co.

Leerink Partners

수요일(23일) 캐시 우드가 이끄는 아크 인베스트는 엔비디아(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>)와 AMD(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>)에 대한 노출을 증가시켰다. 이러한 거래는 반도체 산업에서 지속적인 어려움, 특히 미국의 제재가 중국에 대한 칩 판매에 영향을 미치고 있는 상황에서 이루어졌다.
<h3>엔비디아 거래</h3>
아크 인베스트의 ARK 자율 기술 및 로보틱스 ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKQ#BATS">ARKQ</a>)는 엔비디아 주식 4,731주를 매수했다. 종가는 102.71달러로 마감하며 전날보다 3.86% 상승했다. 이 거래의 총 가치는 약 485,921달러에 달한다. 이 구매는 아크 인베스트가 지닌 엔비디아의 잠재력에 대한 신뢰를 나타내며, 중국의 기술 대기업인 알리바바와 텐센트가 미국의 제재로 인해 엔비디아의 AI 칩을 <a href="https://www.benzinga.com/25/04/44963176/chinese-tech-firms-led-by-alibaba-hoard-nvidia-ai-chips-amid-us-sanctions" target="_blank" rel="noopener">비축하고 있는 상황</a>에서 이루어졌다. 이 칩들은 특히 H20 모델로, 미국의 규제 요건을 충족하도록 설계되었지만, 배송 제한의 위협으로 인해 중국 기업들로부터의 수요가 급증했다.
<h3>AMD 거래</h3>
아크 인베스트의 ARKQ ETF가 AMD 주식 1,808주를 매수했다. AMD의 주가는 4.79% 상승하며 90.39달러로 마감해 이번 매수는 총 163,425달러의 가치가 있다. 이는 AMD가 반도체 분야에서의 입지를 강화하고 있는 가운데 이루어졌다.
화요일에도 이미 아크는 <a href="https://www.benzinga.com/25/04/44940763/ark-invests-bold-moves-nvidia-amd-airbnb-and-microsoft-in-focus" target="_blank" rel="noopener">AMD 주식</a>을 214만 달러 상당 매입했고, 엔비디아 주식은 109만 달러 상당을 매입했다. 두 회사 모두 중국을 겨냥한 미국의 수출 제한을 받고 있다.
<h3>기타 주요 거래</h3>
<ul>
<li>ARKW를 통해 마이크로소프트 주식 182주를 매도했다.</li>
<li>ARKF를 통해 유아이패스(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>) 주식 40,015주, ARKW를 통해 8,273주를 매도했다.</li>
<li>ARKG를 통해 뉴릭스 테라퓨틱스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>) 주식 104,048주를 매수했다.</li>
<li>ARKG ETF에서 어댑티브 바이오테크놀로지스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>) 주식 147,820주를 매도했다.</li>
<li>ARKG ETF를 통해 10X 지노믹스(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>) 주식 80,661주를 매수했다.</li>
</ul>
사진 제공: T. Schneider on Shutterstock.com
이 기사는 <a href="https://www.benzinga.com/author/benzinga-neuro">Benzinga Neuro</a>를 사용하여 생성되었으며, <a href="https://www.benzinga.com/author/shivdeep-dhaliwal">Shivdeep Dhaliwal</a>이 편집했습니다.
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

캐시 우드가 이끄는 아크 펀드(Ark Funds)는 미래 성장 <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/10/41593922/cathie-woods-ark-invest-sees-tesla-unlocking-11-trillion-revenue-potential-with-rob" target="_blank" rel="noopener" data-google-interstitial="false">혁신 분야</a>에 중점을 두고 적극적으로 관리되는 ETF들 덕분에 가장 잘 알려진 펀드 매니저 중 하나이다.
이 펀드의 ETF 두 개가 목요일에 10주년을 맞이했다. 이들 펀드의 출시와 지난 10년 동안의 성과를 살펴보겠다.
아크 이노베이션: 우드와 <a href="https://www.benzinga.com/topic/ark-funds">아크 펀드</a>는 Ark Innovation ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARKK#NYSE">ARKK</a>)를 2014년 10월 31일에 출시했다. 이 펀드는 이 회사의 가장 유명하고 가장 큰 펀드로 성장했으며, 현재 57억 8천만 달러의 운용 자산을 보유하고 있다.
&#8220;ARRK는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 국내 및 해외 주식에 주로 투자하여 펀드의 투자 테마인 파괴적 혁신(disruptive innovation)와 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkk">웹사이트</a>에서 설명한다.
파괴적 혁신 테마에는 자율 이동성, 정밀 치료, 차세대 클라우드, 신경망, 지능형 기기, 디지털 지갑, 디지털 자산, 스마트 계약 및 멀티오믹 기술이 포함된다.
&#8220;ARK는 &#8216;파괴적 혁신&#8217;을 세상이 돌아가는 방식에 잠재적으로 도전할 수 있는 기술적으로 구현된 새로운 제품이나 서비스의 도입으로 정의한다.&#8221;
현재 ARKK ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>테슬라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>): 14.1%</li>
<li>로쿠 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ROKU#NASDAQ">ROKU</a>): 10.8%</li>
<li>코인베이스 글로벌 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COIN#NASDAQ">COIN</a>): 8.1%</li>
<li>로블록스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RBLX#NYSE">RBLX</a>): 6.2%</li>
<li>팔란티어 테크놀로지스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NYSE">PLTR</a>): 5.1%</li>
<li>로빈후드 마켓 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HOOD#NASDAQ">HOOD</a>): 5.0%</li>
<li>블록 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SQ#NYSE">SQ</a>): 4.9%</li>
<li>크리스퍼 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRSP#NASDAQ">CRSP</a>): 4.5%</li>
<li>쇼피파이 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>): 3.9%</li>
<li>유아이패스 (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PATH#NYSE">PATH</a>): 2.9%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 161.4% 상승했다. 이 수익률은 S&amp;P 500을 추적하는 SPDR S&amp;P 500 ETF Trust(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)의 현재 10년 수익률에는 미치지 못한다.
아래의 표는 ARKK의 수익률이 SPY와 어떻게 비교되는지를 보여준다. SPY는 <a href="https://www.benzinga.com/etfs/broad-u-s-equity-etfs/24/10/41407647/spy-reaches-600-billion-in-assets-oldest-us-ETF-hits-milestone-as-all-time-highs-conti">가장 오래되고 가장 큰</a> 미국 ETF이다:
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKK</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>+19.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-24.3%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>+2.6%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKK 설립 이래 2014년 10월 31일 기준</td>
<td>+10.2%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
아래의 차트는 <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1">Benzinga Pro</a>에서 제공한 ARKK의 10년 수익률을 보여준다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624517" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png" sizes="(max-width: 1003px) 100vw, 1003px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224.png 1003w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31133929/Screenshot-224-768x393.png 768w" alt="" width="1003" height="513" /></a></figure>
비교를 위해 SPY의 10년 차트도 보여드리겠다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624522" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png" sizes="(max-width: 995px) 100vw, 995px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226.png 995w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-300x153.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134001/Screenshot-226-768x392.png 768w" alt="" width="995" height="508" /></a></figure>
다음 읽어보기: <a href="https://www.benzinga.com/markets/penny-stocks/23/08/34102486/exclusive-cathie-wood-tells-benzinga-why-tesla-should-trade-as-a-tech-stock">독점: 캐시 우드가 테슬라가 기술 주식으로 거래되어야 하는 이유를 Benzinga에 말했다.</a>
아크 지노믹스: Ark Genomic Revolution ETF(BATS:<a class="ticker" href="https://www.benzinga.com/stock/ARKG#BATS">ARKG</a>)는 2014년 10월 31일에 아크 펀드에 의해 출시되었다. 현재 이 ETF 펀드는 13억 3천만 달러의 자산을 운용하고 있다.
&#8220;ARKG는 자본의 장기적 성장을 추구하는 액티브하게 관리되는 ETF로, 일반적으로 헬스 케어, 정보 기술, 소재, 에너지 및 소비재 등 여러 섹터의 국내외 주식에 주로 투자하며, 펀드의 투자 테마인 유전체 혁명(genomics revolution)과 관련된 회사들에 투자한다&#8221;고 이 회사의 <a href="https://www.ark-funds.com/funds/arkg">웹사이트</a>에서 설명한다.
이 유전체 혁명 ETF의 테마에는 정밀 치료, 멀티오믹 기술, 프로그래머블 생물학, 신경망, 차세대 클라우드 및 적응형 로보틱스가 포함된다.
현재 ARKG ETF의 상위 10개 보유 종목과 그 순자산 비율은 다음과 같다:
<ol>
<li>트위스트 바이오사이언스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWST#NASDAQ">TWST</a>): 8.7%</li>
<li>리커젼 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RXRX#NASDAQ">RXRX</a>): 7.0%</li>
<li>크리스퍼 테라퓨틱스: 7.0%</li>
<li>케어Dx (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDNA#NASDAQ">CDNA</a>): 5.1%</li>
<li>어댑티브 바이오테크놀로지스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADPT#NASDAQ">ADPT</a>): 4.7%</li>
<li>베라사이트 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VYCT#NASDAQ">VYCT</a>): 4.6%</li>
<li>아이오니스 파마슈티컬스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>): 4.3%</li>
<li>누릭스 테라퓨틱스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NRIX#NASDAQ">NRIX</a>): 4.1%</li>
<li>나테라 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRA#NASDAQ">NTRA</a>): 3.8%</li>
<li>10x 지노믹스 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXG#NASDAQ">TXG</a>): 3.8%</li>
</ol>
이 펀드 설립 이래로 이 ETF의 수익률은 38.9% 상승했다. 이 수익률은 현재 SPDR S&amp;P 500 ETF Trust의 10년 수익률에는 미치지 못한다.
ARKG의 수익률이 SPY와 어떻게 비교되는지를 살펴보겠다.
<figure class="wp-block-table">
<table style="overflow:auto; height: 90px; display: block;">
<tbody>
<tr>
<td>평균 연간 수익률</td>
<td>ARKG</td>
<td>SPY</td>
</tr>
<tr>
<td>1년</td>
<td>-7.9%</td>
<td>+36.2%</td>
</tr>
<tr>
<td>3년</td>
<td>-29.9%</td>
<td>+11.8%</td>
</tr>
<tr>
<td>5년</td>
<td>-1.9%</td>
<td>+15.8%</td>
</tr>
<tr>
<td>ARKG 설립 이래 2014년 10월 31일 기준</td>
<td>+3.3%</td>
<td>+13.2%</td>
</tr>
</tbody>
</table>
</figure>
다음은 ARKG의 10년 차트다.
<figure class="wp-block-image size-full"><a href="https://www.benzinga.com/pro/?utm_source=BZprocontent103124&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" class="wp-image-624525" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png" sizes="(max-width: 993px) 100vw, 993px" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225.png 993w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-300x154.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/10/31134031/Screenshot-225-768x394.png 768w" alt="" width="993" height="510" /></a></figure>
중요성 (Why It&#8217;s Important): 위의 차트들은 ARKK와 ARKG가 모두 투자자들에게 몇 년 동안 강력한 성장과 수익률을 경험했지만, 최근 몇 년 동안은 더 넓은 S&amp;P 500 시장 지수를 하회한 것을 보여준다.
한때 이 ETF들은 가장 화제가 된 펀드들 중 하나였으며, 이 회사의 일일 거래 활동은 종종 주식을 상승시켰다. 이는 우드의 뛰어난 성과 덕분이다.
S&amp;P 500 ETF는 분기마다 리밸런싱을 하지만, 이 액티브하게 관리되는 펀드는 거의 매일 거래를 완료한다. 종종 주가가 상승하는 주식의 평균 매입가가 시간이 지남에 따라 상승하여 수익률에 부정적인 영향을 미칠 수 있다.
아크 펀드는 일반적으로 향후 5년에서 10년 동안 강력한 성장을 할 것으로 믿는 회사들에 투자한다. 이는 펀드의 수익률이 때때로 몇 년이 걸려야 나타날 수 있음을 의미한다.
우드는 엔비디아의 주식을 2014년에 약 5달러에 매수한 것과 같이 많은 테마에 대해 일찍 투자한 바 있다. 이는 가장 최근의 주식 분할 이전의 일이었다. 이 펀드는 나중에 2022년 말과 2023년 초에 이 포지션에서 완전히 매도하여 지난 2년 가까이 <a style="font-size: revert;" href="https://www.benzinga.com/general/education/24/02/37294405/heres-how-much-cathie-wood-ark-invest-flagship-fund-missed-by-selling-nvidia-early">엄청난 수익을 놓쳤</a>다.
이 펀드 매니저는 또한 테슬라 성장 스토리에 일찍 투자했다. 2018년 2월에 이 전기차 회사에 대해 $4,000 목표 주가를 <a href="https://www.benzinga.com/news/22/03/26046331/if-you-invested-1-000-in-tesla-when-cathie-wood-made-her-4-000-prediction-heres-how-much-youd-have-n-1" target="_blank" rel="noopener">예측</a>했다. 당시에는 가격 예측으로 비웃음거리가 되었지만, 주가는 2021년 1월에 분할 기준으로 목표 주가에 도달했다.
테슬라에 대한 예측이 맞아들어간 것은 우드의 펀드 매니저로서의 위상을 높이는 데 도움이 되었고, 아크 펀드 ETF들에 대한 관심이 증가하는 계기가 되었다.
최근 몇 년 동안 아크 펀드 ETF들에 대한 관심이 식었지만, 많은 투자자들은 여전히 그들의 영향을 기억하고 일일 거래 활동을 계속 추적하며, 우드가 향후 5년에서 10년 동안 보유할 주식을 주의 깊게 지켜보고 있다.

다음 읽어보기:
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/23/08/34028505/exclusive-why-does-cathie-wood-think-bitcoin-is-going-to-1-million-what-does-she-know-that">독점: 캐시 우드는 왜 비트코인이 100만 달러에 이를 것이라고 생각하는가? 그녀는 무엇을 알고 있기에?</a></li>
</ul>
이미지 제공: Ark Invest 및 Shutterstock.
Benzinga Pro의 독점 뉴스 및 도구로 더 많은 승리를 거두세요 
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. 
<a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor" target="_blank" rel="noreferrer noopener">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

캐시 우드의 아크 이노베이션, 지노믹스 ETF가 10주년을 기념: 연간 수익률을 S&P 500과 비교

Comments

Nurix Therapeutics

뉴스

에 대한 최신 뉴스 Nurix Therapeutics (NASDAQ:NRIX) 주식

목요일, 4월 24, 2025

금요일, 11월 01, 2024

월요일, 10월 14, 2024

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌